Company Encyclopedia
View More
name
Evaxion A/S
EVAX.US
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N.
1.875 T
EVAX.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking150/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-64.99%E
    • Profit Margin-70.82%E
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY132.17%A
    • Net Profit YoY52.73%B
    • Total Assets YoY95.83%A
    • Net Assets YoY22331.08%A
  • Cash ScoreB
    • Cash Flow Margin-141.20%D
    • OCF YoY132.17%A
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreC
    • Gearing Ratio44.18%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Evaxion Announces Positive Data For Lead Antigens In Cytomegalovirus (Cmv) Vaccine Program Evx-V1

    Evaxion A/S:* EVAXION ANNOUNCES POSITIVE DATA FOR LEAD ANTIGENS IN CYTOMEGALOVIRUS (CMV) VACCINE PROGRAM EVX-V1 Source text: Further company coverage:

    Reuters·
    US
    EVAX
    +9.43%
    Reuters·
    US
    EVAX
    +9.43%

    Evaxion Unveils Novel AI-Discovered Antigens Showing Protective Effects in CMV Vaccine Program

    Evaxion A/S has announced positive preclinical results for its CMV vaccine program, EVX-V1, using its AI-Immunology™ platform. The AI-discovered antigens have shown the ability to induce immune responses and inhibit viral infection. The vaccine candidate includes a proprietary pre-fusion glycoprotein B antigen with superior CMV neutralization. Preclinical development continues with further antigen optimization.

    Reuters·
    US
    EVAX
    +9.43%
    Reuters·
    US
    EVAX
    +9.43%

    Evaxion Biotech Increases Share Capital Following Warrant Exercise

    Evaxion Biotech announced a share capital increase on November 4, 2025, following the exercise of investor warrants, issuing 1,875,000 ordinary shares and raising the share capital to DKK 104,252,689. This move aims to strengthen its financial position. The latest analyst rating for EVAX stock is Hold with a $6.50 price target, while TipRanks’ AI Analyst rates it as Neutral due to financial instability and valuation concerns.

    Tip Ranks·
    US
    EVAX
    +9.43%
    Tip Ranks·
    US
    EVAX
    +9.43%

    Evaxion A/S Announces 2026 Financial Calendar

    Evaxion A/S has announced its financial calendar for 2026, detailing key dates for business updates and financial results. This is significant for stakeholders to track the company's progress. The latest analyst rating for EVAX stock is a Buy with a $16.00 price target, while TipRanks' AI Analyst rates it as Neutral due to ongoing losses and reliance on debt. Evaxion specializes in AI-powered vaccines and is focused on innovative treatments for cancer and infectious diseases.

    Tip Ranks·
    US
    EVAX
    +9.43%
    Tip Ranks·
    US
    EVAX
    +9.43%

    Evaxion A/S to Report Full Year 2025 Financial Results

    Evaxion A/S has announced its future financial events, including the release of its full year 2025 financial results on March 5, 2026. Other key dates include the Annual General Meeting on April 16, 2026, and quarterly financial results for Q1, Q2, and Q3 of 2026 scheduled for May 7, August 20, and November 19, respectively. Results will be available on the company website.

    Reuters·
    US
    EVAX
    +9.43%
    Reuters·
    US
    EVAX
    +9.43%